Brief: Lantern Pharma Reports First Quarter 2023 Financial Results
09/05/2023 21:22
May 9 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS AND
OPERATIONAL HIGHLIGHTS
* LANTERN PHARMA INC - $51.5 MILLION IN CASH, CASH
EQUIVALENTS,
AND MARKETABLE SECURITIES AS OF MARCH 31, 2023
* LANTERN PHARMA INC - HAS A CASH RUNWAY INTO 2025
* LANTERN PHARMA INC - QTRLY LOSS PER SHARE $0.36
Source text for Eikon: ID:nBw85LQ1ga
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments